Featured post

SCS research and awards news

For all our research and awards news, please visit our news page.

Monday, 13 March 2017

ECR Symposium - Monday 30th October 2017 - SAVE THE DATE

The Faculty of Medicine Nursing and Health Sciences (FMNHS) will be holding their biennial Early Career Researcher (ECR) Symposium on Monday 30th October 2017 at the Monash Business School, 271 Collins Street (Level 7), Melbourne.

Please save the date and advertise the flyer in your respective areas.

This event will comprise of seminars and workshops encompassing:
  • strategic career planning
  • engaging with industry
  • grant writing tips and 
  • networking events specifically designed for Early Career Researchers.

Registrations for this event will open mid August 2017.

CID Weekly Seminar Series: Dr Michaela Finsterbusch and Mr SJ Shen, Tuesday 14 March

12 - 1pm, Tuesday 14 March, Seminar Room 1, TRF Building

Dr Michaela Finsterbusch, Research Fellow, Centre for Inflammatory Diseases

Platelet accumulation and interactions with neutrophils in acute glomerulonephritis

Glomerulonephritis is a leading cause of end-stage renal failure. In this disease immune cells (e.g. neutrophils in acute glomerulonephritis) are incorrectly activated and start to fight against us by attacking and damaging tissue in the kidney. We believe that cross-talk between different cells (e.g. between platelets and neutrophils) initiate neutrophil-dependent inflammation and the release of harmful factors such as reactive oxygen species. To study the behaviour and distinct role of these cell types in the healthy glomerulus and during acute glomerular inflammation, we use highly advanced microscopy techniques, allowing us to visualise these cells in real-time in the live organ. We hope that data arising from this work will help to better understand the cause of glomerulonephritis and help to develop more effective and saver therapies to block these injurious pathways in patients.

Michaela joined Prof. Michael Hickey's group at the Centre for Inflammatory Diseases, Monash University in 2014 as a research fellow to study immune-modulatory mechanisms of leukocytes in experimental glomerulonephritis. Michaela trained at the University of Applied Sciences in Vienna and graduated with a Master's degree in biomedicine/analytics. During her Master's thesis Michaela studied IL-10 signalling specifically through common IL-10 receptor 1 variants in Prof. Christoph Gasche's lab at the Medical University of Vienna (Department of Gastroenterology). After graduating, Michaela moved to London to do her PhD with Prof. Sussan Nourshargh (William Harvey Research Institute) investigating immune and vascular functions in experimental models of inflammation on a three year British Heart Foundation-funded PhD scholarship. She completed her PhD in 2013 and stayed in London for another year to work in Prof. Amrita Ahluwalia's lab on the transient receptor potential cation channel subfamily V member 1 (TRPV1).   
In 2014, Michaela was recruited to Monash University by Prof. Michael Hickey to study the involvement of and communication between different immune cells (e.g. neutrophils, monocytes, platelets) in acute glomerulonephritis. For her work, Michaela primarily uses highly advanced microscopy techniques (i.e. spinning disc and multiphoton confocal microscopy) to visualise different cell types and analyse their behaviour in the live organ.

In 2015, Michaela has been successfully awarded an Erwin Schroedinger fellowship funded by the Austrian Science Fund.

AND
Mr SJ Shen, Postgraduate student, Centre for Inflammatory Diseases – milestone review

Investigating the impact of neutrophil recruitment on colonic inflammation

Inflammatory bowel disease (IBD) is a group of idiopathic, chronic and relapsing inflammatory disease, and includes primarily Crohn’s Disease (CD) and Ulcerative Colitis (UC). There is currently no cure, and disease management strategies only alleviate the symptoms. Patients with IBD have severe complications such as weight loss, fatigue, bloody stools, and diarrhoea. These symptoms arise from activation and potentiation of an abnormal immune response, whereby immune cells are recruited to the gut and damage the gut tissue.
One cell type of interest is neutrophils, where high numbers have been associated with disease. This is also the general consensus in the dextran sodium sulphate (DSS)-induced colitis model, a well-established mouse model of UC, which recapitulates the pathological signs of the human disease.
We now know changes in the gut microbiota affect immune cells such as regulatory T cells and invariant natural killer T (iNKT) cells. Studies have elucidated a clear beneficial role of regulatory T cells in colitis, but the role of iNKT cells is less well-defined. Therefore, the first aim of my project is on exploring the role of iNKT cells on leukocyte recruitment following DSS-induced colitis.
Given the link between the gut microbiota and colitis, modulation of the microbial composition may affect disease progression. In fact, recent research has revealed anti-inflammatory properties of fibre and its fermented products short-chain fatty acids. However, less is known about the impact of a lack of fibre and whether that is a risk factor for the plethora of inflammatory diseases. Thus, the second aim of my project is on examining how a lack of fibre changes the physiology to be more prone to inflammation.

Sj Shen is currently a second year PhD candidate at Monash Medical Centre (Clayton), supervised by Dr. Connie Wong and Prof. Michael Hickey, with a research interest in the effect of dietary fibre in a mouse model of Inflammatory Bowel Disease. He completed Bachelor of Biomedical Sciences at Monash University (Clayton), which included a unit of third year research examining the role of fibre in a mouse model of asthma, taken under the supervision of Dr. Alison Thorburn. Sj then undertook an Honours year with the Department of Immunology (Clayton) at Monash University in the same lab, with research focus on the effect of diet in experimental eosinophilic oesophagitis.

A light lunch is served prior to the seminar at 11:45am in the seminar room foyer, level 2, TRF Building.


Further information, including the link to add the seminar series to your google calendar, is available from CID Weekly Seminar Series website [http://www.med.monash.edu.au/scs/medicine/cid/seminar-series.html]

Winston S. Rickards Memorial Oration, “Advocating on the Edge: Three Quarters of a Century of the Children’s Court Clinic in Victoria”. 20 March

The Winston S. Rickards Memorial Oration, to be delivered by Dr Patricia Brown, Clinical Psychologist, on Monday, 20th March 2017 at 7.30pm in the Ella Latham Theatre, The Royal Children’s Hospital, Flemington Road, Parkville, Victoria.


As Clinical Director of the Children’s Court Clinic in the Department of Justice, Victoria, Dr Brown is well known across Australia and overseas as a champion of the rights and wellbeing of the most vulnerable children and young people in our communities. These are of course those who may be, or have been, removed from the care of their parents, and those who may have committed serious crimes. Her understanding of the complex societal and psychological issues underlying the difficulties faced by these children and teenagers, and her compassion for them in the context of their encounter with the Children’s Court, are nothing short of inspirational. In the Oration, Dr Brown will speak of the challenges in responding to the requests of the Clinic made by the Children’s Court Magistrates, and in advocating for the psychological needs of the children and young people involved, often in controversial circumstances. She will also describe her role in advancing the practice of the Clinic, and in shaping forensic clinical psychology as a specialisation in Australia.

The event is free, but it would be appreciated if you could RSVP to Jacinta.Bleeser@gmail.com or celia.godfrey@mcri.edu.au

Hudson Seminar Series, "Sorting out the skeleton: the role of intracellular trafficking in bone homeostasis and disease", 16 March

12 - 1pm, Thursday 16 March, Seminar rooms 1 & 2, TRF building

The speaker will be Associate Professor Nathan Pavlos, Deputy Director (Research) and Head, Cellular Orthopaedic Laboratory, Centre for Orthopaedic Research, School of Surgery, University of Western Australia.
Associate Professor Pavlos completed his undergraduate and PhD studies in bone cell biology at UWA. In 2007, he was awarded a NHMRC CJ Martin (Biomedical) Overseas Research Fellowship and carried out his postdoctoral training at the Max Planck Institute (MPI) for Biophysical Chemistry, Germany, from 2007-2009 with Professor Reinhard Jahn, where he worked on the molecular regulation of synaptic vesicle exo-endocytosis in neurons. In 2010, A/Professor Pavlos returned to UWA to form his own laboratory within the Centre for Orthopaedic Research.
A/Professor Pavlos’ current research interests focus on the molecular mechanisms of bone-resorbing osteoclasts, the major cellular protagonists underlying a number of highly debilitating musculoskeletal diseases including osteoporosis, osteoarthritis, Paget's disease and tumour-mediated bone loss. Along with his focus on osteoclasts and bone biology, he also has a long-standing interest in the molecular regulation and dynamics of protein trafficking, a process essential for normal cellular function and often perturbed in many different diseases.

A light lunch and refreshments will follow the presentation. 

PhD confirmation, Manjeet Sandhu, "A prospective study to assess the role of IL-38 in Inflammatory Bowel Disease patients", 16 March

All staff and students are invited to Manjeet Sandhu's PhD confirmation

16th March 2017, 2,30pm-4.30pm. Hudson Institute Level 3 Bridge rooms 1a 1b

 Synopsis:  Inflammatory Bowel Disease is a chronic inflammatory condition with a severe impact on quality of life for which there is no treatment other than non-specific immunosuppression with glucocorticoids and biologic therapies that themselves have multiple adverse effects on the patient. Emerging evidence from our laboratory suggests that IL-38 may prove to be an effective anti-inflammatory agent in IBD. In order to assess its therapeutic prospects, my PhD aims to characterise the abundance of IL-38 in peripheral blood and the intestine of patients with IBD. We further aim to validate the impact of IL-38 in mouse models of IBD    

SupervisorsDr Gregory Moore (main), A/Prof Marcel Nold, Dr Claudia Nold, Dr Ina Rudloff



PhD mid-candidature review seminar Ella Ottrey, "Meal realities - Exploring mealtime complexity on the subacute hospital ward", 28 March

All staff and students are invited to Ella Ottrey's progress / mid-candidature review seminar.

Tuesday 28 March, 1.30pm, Tamarillo Room, Level 1, BASE Facility, Notting Hill


Presentation Title: Meal realities - Exploring mealtime complexity on the subacute hospital ward

Synopsis: Inadequate food intake is a complex and challenging issue in the hospital setting. A variety of interventions have been implemented to address this problem with little success to date. In order to more effectively address inadequate food intake, a better understanding of hospital mealtimes and the context to which these interventions are being applied is needed. This research aims to explore and understand patterns of mealtime culture, environment and social practice from the perspective of staff, volunteers and visitors on the subacute hospital ward.

Supervisors: A/Prof Claire Palermo, Dr Kate Huggins, Associate Professor Judi Porter

Panel chair: Dr Ricardo Costa


Independent assessors: Prof Lisa McKenna, A/Prof Karen Walton

PhD milestone review, Sushena Krishnaswamy, "Implementing antenatal pertussis vaccination: has it been well adopted, and how can we improve uptake?" 31 March

All staff and students are invited to Sushena Krishnaswamy's PhD milestone review.

1-2pm, Friday 31 March, Monash Infectious Diseases Seminar, Pathology Conference Room, Level 3, Monash Medical Centre


Synopsis: Antenatal vaccination is the most effective strategy to decrease pertussis infections in the most vulnerable population, infants less than 3 months of age. My PhD examines various aspects of implementing antenatal vaccination programs- from attitudes and knowledge of consumers and antenatal care providers, to service delivery models, to feasibility of real time adverse event surveillance.  This presentation will predominantly cover a sub-study, the uptake of vaccination by the mother and other significant contacts of newborns.


Supervisor name: A/Prof Michelle Giles, Prof Euan Wallace, A/Prof Jim Buttery

Resilience and stress in raising a child with developmental disabilities, 28 and 30 March


Intensive Research Ethics Course, 4-8 June 2017 in NSW

Sunday 4 June– Thursday 8 June, 2017 at Peppers Craigieburn, Bowral NSW

This intensive course is designed to assist researchers, ethics committee members and others involved in the conduct and assessment of research to understand and clarify the issues arising in relation to research of all kinds involving human participants. It will provide an opportunity for members of research and research ethics communities to come together to discuss the issues they face and share their experiences.

The course aims to give registrants an appreciation of the philosophical and ethical issues underlying research involving human participants, an understanding of the issues relating to different research methodologies and research involving special populations.
The program will be interactive and will include small group discussions and workshops. There will be ample provision for free time to encourage further discussion and debate among participants.

The Venue
Within easy reach of Sydney, Canberra and the coast, Peppers Craigieburn is set in the beautiful Southern Highlands, an area renowned for its national parks, antique shopping and cool climate wines.

More information HERE.  Registration form HERE.

Exercise, vitamin D and musculoskeletal and cardiovascular health study

PhD student Alexander Rodriguez and BMedSc Honours Student Cecilia Xu from the Bone and Muscle Health Research Group are conducting a randomised controlled trial investigating if vitamin D enhances the benefits of exercise for musculoskeletal and cardiovascular health in middle-aged and overweight older adults with low vitamin D status.

The study will measure bone density, body composition and aortic calcification on DXA (a type of X-ray) as well as a number of physical performance and strength indicators.
Participants will be randomly allocated to12 weeks of taking vitamin D supplements or a placebo, and all participants subsequently complete 12 weeks of exercise which includes one supervised class at the Monash Medical Centre (Clayton) and two classes at home per week. Instruction and telephone guidance and support is given to all participants throughout the study.

All participants will be provided with the results of their body composition and cardiovascular assessments as well as have all transport costs reimbursed.  

Eligibility criteria include being aged between 50 and 80 years; having a body mass index (BMI) between 25 and 40 kg/m2 and having low vitamin D (which is measured at Monash Medical Centre).

If you, your patients, family members or friends might be interested in this study, please contact Alexander or Cecilia:

Phone: 8572 2919

The Australian Lupus Registry and Biobank: a timely initiative

Eric Morand, Alberta Hoi et al. published in the Medical Journal of Australia.

Read article here.

Interferon-free treatment for HCV infection: are we on the road to elimination?

William Sievert published in the Internal  Medicine Journal

Read article here.

The factor structure and use of the Demoralization Scale (DS-IT) in Italian cancer patients

David Kissane et al. published in Psycho-Oncology.

Read article here.

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Jake Shortt et al. published in Cell Reports.

Read article here.

Observational study of alternative therapies among paediatric emergency department patients

Simon Craig et al. published in Emergency Medicine Australasia.

Read article here.

Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene

Jake Shortt et al. published in Nature Communications.

Read article here.

A systematic review of studies with a representative sample of refugees and asylum seekers living in the community for participation in mental health research

Joanne Enticott et al. published in BMC Medical Research Methodology.

Read article here.

Kawasaki disease and immunisation: A systematic review

David Burgner, Jim Buttery et al. published in Vaccine.

Read article here.

Monday, 6 March 2017

3MT presentation - Stuart Emerson talks about pelvic organ prolapse.

Watch Stuart's presentation...

Combination of ground-breaking treatments offer powerful new path for blood cancer therapies

Associate Professor Jake Shortt, Monash University
Researchers at Monash University and Peter MacCallum Cancer Centre have identified for the first time how a new class of epigenetic drug engages with the immune system to kill off cancer cells, offering powerful new pathways for enhanced blood cancer therapies.

BET-inhibitors are a relatively new class of drug which work to ‘switch off’ important cancer-causing genes expressed within tumour cells. International clinical trials of BET-inhibitors for the treatment of blood cancers, such as Acute Myeloid Leukaemia, are now underway including at Monash and Peter Mac.  However to date, this research has focused on the direct effects of the drugs in inducing cancer cell death and understanding how resistance emerges.

In research published last week in Cell Reports, the team at Peter Mac and Monash have demonstrated the potential for combining ground-breaking epigenetic and immune-based treatments for more potent results.

Experiments conducted as part of the research, showed that immune-competent mice with lymphoma had a far greater response to BET-inhibitors than their immune-deficient counterparts.

In addition to their primary function, the research showed the BET inhibitors were able to ‘switch off’ a protein called PD-L1, which is used by tumour cells to hide from the immune system. Through this mechanism, the BET-inhibitors were making tumour cells more sensitive to attack from the immune system.

The power of an activated immune system in eliminating tumour cells has been proven through ‘blockbuster’ drugs such as ‘Keytruda’ and ‘Opdivo’, which also target the PD-L1 pathway. Building on this knowledge, this research confirmed that the combinations of BET-inhibitor with other immune therapies work better in lymphoma than either therapy alone.

Based on laboratory research performed at Peter Mac, the Monash team is currently trialling a combination of a different epigenetic drug called Dinaciclib with the anti-PD1 therapy, Keytruda in relapsed lymphoma, myeloma and chronic lymphocytic leukaemia with further clinical trials for the combination therapy likely to emerge as a result of this research.


This research was supported by the National Health and Medical Research Council of Australia; Victorian Cancer Agency; Cancer Council Victoria; Snowdome Foundation, The Kids Cancer Project, and Roche. Core technologies enabling the research are supported by the Australian Cancer Research Foundation and Peter MacCallum Cancer Foundation.